Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese rats
Ontology highlight
ABSTRACT: This study evaluates whether simultaneously activating five key metabolic hormone receptors can outperform current peptide therapies for obesity. Using diet‑induced obese rats, we test the combined administration of retatrutide, a GLP‑1, GIP, and glucagon triagonist, together with cagrilintide, an amylin and calcitonin receptor agonist, versus its monotherapies and evaluate the bulk transcriptomic profile of the hypothalamus and the dorsal vagal complex.
INSTRUMENT(S): Illumina NovaSeq 6000
ORGANISM(S): Rattus norvegicus
SUBMITTER: Single Cell Omics Platform CBMR
PROVIDER: E-MTAB-16695 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA